Pre-clinical data are non-catalytic for stock price; the next material catalyst is clinical trial initiation or topline data in ANCA-associated vasculitis. Monitor for Phase 2/3 trial starts or regulatory interactions.
Price Chart
Executive Summary
InflaRx presented pre-clinical data at Kidney Week 2026 showing izicopan reduced renal injury markers in two hamster kidney disease models. The data are early-stage and non-clinical, providing no new revenue, earnings, or regulatory catalyst. The filing is a routine scientific update with no material financial impact.
Key Facts
- Pre-clinical data on izicopan presented at ASN Kidney Week 2026 (Oct 21-25) in Denver.
- In renal IRI hamster model, izicopan significantly reduced creatinine and BUN (p<0.001) and improved histopathological scores (p<0.05).
- In UUO nephropathy model, izicopan significantly reduced BUN (p<0.001) and improved total H&E score (p<0.05).
- Structural modeling suggests izicopan has reduced CYP3A4/5 time-dependent inhibition vs avacopan.
- Company plans development of izicopan in ANCA-associated vasculitis and additional renal indications.
- No financial data, guidance, or regulatory milestones disclosed in this press release.
Financial Impact
No financial figures disclosed; pre-clinical data only.
Risk Factors
- Pre-clinical results may not translate to human clinical efficacy.
- No timeline provided for clinical development in renal indications.
- Competition from avacopan and other C5aR inhibitors.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3386711 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $1.56 | awaiting T+20 | — | $1.58 (+0.96%) |
Oct 22, 2026 4d ago | Press Release | $1.53 | awaiting T+20 | — | $1.58 (+2.94%) |
Oct 2, 2026 24d ago | Press Release | $1.72 | awaiting T+20 | — | $1.58 (−8.43%) |
Oct 1, 2026 25d ago | Press Release | $1.71 | awaiting T+20 | — | $1.58 (−7.89%) |
Aug 14, 2026 10w ago | 424B5 | $2.07 $2.02 | ▲ +2.42% | ▲ +0.44% | $1.58 (+23.91%) |
Aug 13, 2026 10w ago | EFFECT | $2.01 $2.09 | ▼ −3.98% | ▼ −5.73% | $1.58 (+21.64%) |
Aug 6, 2026 11w ago | 6-K | $1.72 $2.23 | ▲ +29.65% | ▲ +29.05% | $1.58 (−8.43%) |
Jun 30, 2026 16w ago | 6-K | $2.33 $1.65 | ▼ −29.18% | ▼ −27.00% | $1.58 (−32.40%) |
Jun 30, 2026 16w ago | Press Release | $2.24 $1.70 | ▼ −24.11% | ▼ −23.08% | $1.58 (−29.69%) |
May 6, 2026 24w ago | 424B5 | $2.65 $2.06 | ▲ +22.26% | ▲ +25.40% | $1.58 (+40.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers